Supplementary Information file

Initial set of Western blot experiments

(full-length, original, unprocessed versions of blots)

Patients	Group	Patient	Sample	Weight of bone
		N⁰	labelling	tissue sample, g
Patients	#1 – bone tissue,	1	1-1	0.0457
with	that was taken from	3	1-2	0.0522
normally	the area of the	4	1-3	0.0674
erupted	normally erupted	5	1-4	0.0575
teeth	third molar	6	1-5	0.0661
	(control group)	8	1-6	0.0355
Patients	#2 – bone tissue of	9	2-1	0.0341
with tooth	patients with	10	2-2	0.0481
impaction	tooth impaction,	11	2-3	0.0452
	collected from the	12	2-4	0.0503
	area of the normally	13	2-5	0.0388
	erupted third molar	14	2-6	0.0426
	#3 – bone tissue of	15	3-1	0.0513
	patients with	16	3-2	0.0641
	tooth impaction,	17	3-3	0.0852
	collected from the	18	3-4	0.0374
	area of the impacted	19	3-5	0.0371
	third molar	20	3-6	0.0509

Table 1 Sample labelling

Fig. 1 Raw data from Western blot experiments using RANK antibody

Immunoblotting was conducted with primary antibody against RANK (1:500; sc-9072, Santa Cruz, USA). Samples are labelled (according to the Table 1) under the images.



1-1 1-2 1-3 2-1 2-2 2-3 3-1 3-2 3-3



Fig. 2 Raw data from Western blot experiments using osteoprotegerin (OPG) antibody

Immunoblotting was conducted with primary antibody against OPG (1:250; sc-8468, Santa Cruz, USA). Samples are labelled (according to the Table 1) under the image.



10 sec exposition

30 sec exposition



Fig. 3 Raw data from Western blot experiments using osteocalcin (OC) antibody

Immunoblotting was conducted with primary antibody against OC (1:500; sc-18319, Santa Cruz, USA). Samples are labelled (according to the Table 1) under the image.

osteocalcin, 5.5 kDa state from these states income states 1-1 1-2 1-3 3-1 3-2 3-3 2-1 2-2 2-3 25 sec exposition osteocalcin, 5.5 kDa 1-1 1-2 1-3 3-1 3-2 3-3 2-1 2-2 2-3 osteocalcin, 5.5 kDa 1-4 1-5 1-6 2-4 2-5 2-6 3-4 3-5 3-6

10 sec exposition

Fig. 4 Raw data from Western blot experiments using RANKL antibody

Immunoblotting was conducted with primary antibody against RANKL (1:250; sc-7628, Santa Cruz, USA). Samples are labelled (according to the Table 1) under the image.



Fig. 5 Raw data from Western blot experiments using NF-*k*B antibody

Immunoblotting was conducted with primary antibody against NF- κ B p65 subunit (1:500; MA5-16160, Thermo Fisher Scientific, USA). Samples are labelled (according to the Table 1) under the image.



Fig. 6 Raw data from Western blot experiments using NFATc1 antibody

Immunoblotting was conducted with primary antibody against NFATc1 (1:1000; MA3-024, Thermo Fisher Scientific, USA). Samples are labelled (according to the Table 1) under the image.



1-4 1-5 1-6 3-4 3-5 3-6 2-4 2-5 2-6

Fig. 7 Raw data from Western blot experiments using caspase-3 antibody

Immunoblotting was conducted with primary antibody against caspase-3 (1:500; sc-373730, Santa Cruz, USA). Samples are labelled (according to the Table 1) under the image.



1-1 1-2 1-3 3-1 3-2 3-3 2-1 2-2 2-3



1-4 1-5 1-6 3-4 3-5 3-6 2-4 2-5 2-6